JnJ seeks USFDA approval for Tremfya label update Ruchika Sharma30 July 2025 3:30 PM ISTSubmission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated with TREMFYA.
Guselkumab shows superior efficacy and offers new hope to Crohn's disease patients in landmark clinical trials Dr. Kamal Kant Kohli23 July 2025 8:15 PM IST In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication...
Guselkumab Effective and Long-Lasting Psoriasis Treatment Across All Skin Tones, suggests study Jacinthlyn Sylvia9 July 2025 8:30 PM ISTA new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable treatment for psoriasis,...
Janssen-Cilag Guselkumab receives UK nod for Crohn's disease, ulcerative colitis Ruchika Sharma20 May 2025 2:45 PM ISTJanssen-Cilag Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for guselkumab (Tremfya) to treat...
Johnson and Johnson Gets CDSCO Panel Nod To study Guselkumab in Psoriatic Arthritis Dr. Divya Colin17 Feb 2025 5:00 PM ISTNew Delhi: Pharmaceutical major Johnson and Johnson has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
Guselkumab effective and safe treatment option for psoriasis patients, Study finds Jacinthlyn Sylvia30 Jan 2025 8:30 PM ISTA recent study reaffirmed the safety and effectiveness of guselkumab, in managing psoriasis and psoriatic arthritis over an extended period of 208...
JnJ seeks USFDA nod for Tremfya for treatment of plaque psoriasis, juvenile psoriatic arthritis in children Ruchika Sharma3 Dec 2024 12:30 PM ISTSpring House: Johnson & Johnson has announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and...
JnJ seeks USFDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis Ruchika Sharma29 Nov 2024 11:30 AM ISTSpring House: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
JnJ Tremfya receives USFDA approval for adults with moderately to severely active ulcerative colitis Ruchika Sharma12 Sept 2024 12:30 PM ISTHorsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA (guselkumab) for the treatment of...
JnJ seeks USFDA approval for Tremfya for moderately to severely active Crohn's disease Ruchika Sharma22 Jun 2024 2:21 PM ISTSpring House: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
JnJ submits regulatory applications to EMA for Tremfya for treatment of patients with ulcerative colitis, Crohn's disease Ruchika Sharma5 May 2024 1:30 PM ISTBeerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced it has submitted applications to the European Medicines...
Bimekizumab bests Guselkumab in psoriatic arthritis, reveals new study Dr. Shravani Dali5 April 2024 11:00 PM ISTBimekizumab bests Guselkumab in psoriatic arthritis, reveals new study published in the Rheumatology and Therapy.Matching-adjusted indirect...
